BACKGROUND: Airway inflammation in chronic obstructive pulmonary disease (COPD) is predominately neutrophilic, but some subjects demonstrate eosinophilic airway inflammation. Whether these inflammatory phenotypes have differential cytokine and chemokine expression is unknown. OBJECTIVES: To assess the sputum concentrations of cytokines and chemokines and their response to oral corticosteroid therapy in COPD subjects with or without a sputum eosinophilia. METHODS: Cytokine and chemokine concentrations were measured using the meso-scale device platform. To assess validity, recovery of exogenous spikes was examined. The concentrations of the validated mediators were measured in COPD sputum from subjects with or without a sputum eosinophilia. In a subgroup with a sputum eosinophilia, the response to oral prednisolone 10 mg for 1 month was examined. RESULTS: The recovery in sputum of exogenous spiked mediators was >80% in 11/26 cytokines and chemokines. In supernatants from eosinophilic (n = 39) versus non-eosinophilic (n = 59) sputa, the geometric mean (95% CI) concentration was increased for IL-5 [9.0 (4.5-18) pg/ml vs. 3.6 (2.7-6.3) pg/ml, p = 0.03]. IL-5 alone was correlated with sputum eosinophil counts (r = 0.33, p = 0.001), and was attenuated following treatment with prednisolone [n = 9; mean difference 2.3 pg/ml (0.2-4.3), p = 0.032]. CONCLUSION: We have validated the use of the meso-scale device platform for cytokine and chemokine measurements in the sputum supernatants in COPD. Sputum IL-5 was associated with a sputum eosinophilia and was attenuated following oral corticosteroid therapy. Whether this cytokine is important in the pathogenesis of COPD in a subgroup of patients warrants further investigation. (c) 2009 S. Karger AG, Basel.
BACKGROUND: Airway inflammation in chronic obstructive pulmonary disease (COPD) is predominately neutrophilic, but some subjects demonstrate eosinophilic airway inflammation. Whether these inflammatory phenotypes have differential cytokine and chemokine expression is unknown. OBJECTIVES: To assess the sputum concentrations of cytokines and chemokines and their response to oral corticosteroid therapy in COPD subjects with or without a sputum eosinophilia. METHODS: Cytokine and chemokine concentrations were measured using the meso-scale device platform. To assess validity, recovery of exogenous spikes was examined. The concentrations of the validated mediators were measured in COPD sputum from subjects with or without a sputum eosinophilia. In a subgroup with a sputum eosinophilia, the response to oral prednisolone 10 mg for 1 month was examined. RESULTS: The recovery in sputum of exogenous spiked mediators was >80% in 11/26 cytokines and chemokines. In supernatants from eosinophilic (n = 39) versus non-eosinophilic (n = 59) sputa, the geometric mean (95% CI) concentration was increased for IL-5 [9.0 (4.5-18) pg/ml vs. 3.6 (2.7-6.3) pg/ml, p = 0.03]. IL-5 alone was correlated with sputum eosinophil counts (r = 0.33, p = 0.001), and was attenuated following treatment with prednisolone [n = 9; mean difference 2.3 pg/ml (0.2-4.3), p = 0.032]. CONCLUSION: We have validated the use of the meso-scale device platform for cytokine and chemokine measurements in the sputum supernatants in COPD. Sputum IL-5 was associated with a sputum eosinophilia and was attenuated following oral corticosteroid therapy. Whether this cytokine is important in the pathogenesis of COPD in a subgroup of patients warrants further investigation. (c) 2009 S. Karger AG, Basel.
Authors: J Y Lacoste; J Bousquet; P Chanez; T Van Vyve; J Simony-Lafontaine; N Lequeu; P Vic; I Enander; P Godard; F B Michel Journal: J Allergy Clin Immunol Date: 1993-10 Impact factor: 10.793
Authors: M Saetta; A Di Stefano; P Maestrelli; G Turato; C E Mapp; M Pieno; G Zanguochi; G Del Prete; L M Fabbri Journal: Clin Exp Allergy Date: 1996-07 Impact factor: 5.018
Authors: Alberto Papi; Cinzia Maria Bellettato; Fausto Braccioni; Micaela Romagnoli; Paolo Casolari; Gaetano Caramori; Leonardo M Fabbri; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2006-02-16 Impact factor: 21.405
Authors: D Miotto; M P Ruggieri; P Boschetto; G Cavallesco; A Papi; I Bononi; C Piola; B Murer; L M Fabbri; C E Mapp Journal: Eur Respir J Date: 2003-10 Impact factor: 16.671
Authors: C Moermans; C Bonnet; E Willems; F Baron; M Nguyen; M Henket; J Sele; J-L Corhay; Y Beguin; R Louis Journal: Bone Marrow Transplant Date: 2014-07-28 Impact factor: 5.483
Authors: Neil E Alexis; John C Lay; Milan Hazucha; Bradford Harris; Michelle L Hernandez; Philip A Bromberg; Howard Kehrl; David Diaz-Sanchez; Chong Kim; Robert B Devlin; David B Peden Journal: Inhal Toxicol Date: 2010-06 Impact factor: 2.724
Authors: Christopher E Brightling; Eugene R Bleecker; Reynold A Panettieri; Mona Bafadhel; Dewei She; Christine K Ward; Xiao Xu; Claire Birrell; René van der Merwe Journal: Lancet Respir Med Date: 2014-09-07 Impact factor: 30.700
Authors: M Bafadhel; M McCormick; S Saha; S McKenna; M Shelley; B Hargadon; V Mistry; C Reid; D Parker; P Dodson; M Jenkins; A Lloyd; P Rugman; Paul Newbold; C E Brightling Journal: Respiration Date: 2011-09-07 Impact factor: 3.580
Authors: Evy E Blomme; Sharen Provoost; Elise G De Smet; Katrien C De Grove; Hannelore P Van Eeckhoutte; Joyceline De Volder; Philip M Hansbro; Matteo Bonato; Marina Saetta; Sara Ra Wijnant; Fien Verhamme; Guy F Joos; Ken R Bracke; Guy G Brusselle; Tania Maes Journal: Clin Transl Immunology Date: 2021-06-05